GnRH for Luteal Support - Mechanism of Action
This prospective observational study will include women undergoing IVF treatment with a GnRH antagonist protocol and fresh embryo transfer at the IVF unit of Shaare Zedek Medical Center. Patients will undergo controlled ovarian stimulation followed by ovulation triggering with hCG, GnRH agonist, or dual trigger accordi
| Condition(s) | GnRH Antagonist IVF Protocol, Fresh Embryo Transfer, Administration of Hormonal Luteal Support |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This prospective observational study will include women undergoing IVF treatment with a GnRH antagonist protocol and fresh embryo transfer at the IVF unit of Shaare Zedek Medical Center. Patients will undergo controlled ovarian stimulation followed by ovulation triggering with hCG, GnRH agonist, or dual trigger according to OHSS risk. After oocyte retrieval and fertilization by IVF/ICSI, embryos will be cultured and transferred. Luteal phase support will consist of either intranasal GnRH agonist (Synarel) or vaginal progesterone. Blood and follicular fluid samples will be collected at predefined time points to assess hormonal, inflammatory, and angiogenic markers, including LH, FSH, estradiol, progesterone, IL-6, IL-8, VEGF, PEDF, and relaxin. |
| Who can participate | Inclusion Criteria: * Women included in the study will be 18-45 years old * undergoing IVF treatments due to ovulation disorder, mechanical factor, primary ovarian insufficiency, or male infertility. * All women will be at their first to the third cycle of treatment * women will undergo a fresh ET. Exclusion Criteria: * repeated implantation failure (more than 3 cycles of good quality ET without implantation) * moderate-severe endometriosis * hydrosalpinx * fibroid uterus * BMI more than 35 or less than 19 * women with hypogonadotropic hypogonadism * PGT of embryos * use of surgical techniques for sperm retrieval * preference of the long GnRH-agonist protocol * women with rhinitis or nasal congestion. |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Heli Alexandroni |
| Locations | Jerusalem, Israel |
| Start date | 2026-05-18 |
| NCT ID | NCT07620067 |
| Official listing | https://clinicaltrials.gov/study/NCT07620067 |